ZA968170B - Method for transferring genes to the heart using aav vectors - Google Patents

Method for transferring genes to the heart using aav vectors

Info

Publication number
ZA968170B
ZA968170B ZA968170A ZA968170A ZA968170B ZA 968170 B ZA968170 B ZA 968170B ZA 968170 A ZA968170 A ZA 968170A ZA 968170 A ZA968170 A ZA 968170A ZA 968170 B ZA968170 B ZA 968170B
Authority
ZA
South Africa
Prior art keywords
heart
aav vectors
transferring genes
genes
transferring
Prior art date
Application number
ZA968170A
Other languages
English (en)
Inventor
Michael G Kaplitt
Martin J Kaplitt
Edward B Diethrich
Original Assignee
Univ Rockefeller
Martin J Kaplitt
Edward B Diethrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Martin J Kaplitt, Edward B Diethrich filed Critical Univ Rockefeller
Publication of ZA968170B publication Critical patent/ZA968170B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
ZA968170A 1995-09-27 1996-09-27 Method for transferring genes to the heart using aav vectors ZA968170B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/534,351 US6162796A (en) 1995-09-27 1995-09-27 Method for transferring genes to the heart using AAV vectors

Publications (1)

Publication Number Publication Date
ZA968170B true ZA968170B (en) 1997-07-21

Family

ID=24129676

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA968170A ZA968170B (en) 1995-09-27 1996-09-27 Method for transferring genes to the heart using aav vectors

Country Status (7)

Country Link
US (1) US6162796A (xx)
EP (1) EP0859853A1 (xx)
JP (1) JPH11512608A (xx)
AU (1) AU727835B2 (xx)
CA (1) CA2233167A1 (xx)
WO (1) WO1997012050A1 (xx)
ZA (1) ZA968170B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306830B1 (en) 1996-09-05 2001-10-23 The Regents Of The University Of California Gene therapy for congestive heart failure
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
US7745416B2 (en) * 1995-04-11 2010-06-29 The Regents Of The University Of California Method for in vivo regulation of cardiac muscle contractility
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US20030206891A1 (en) * 1995-06-07 2003-11-06 Ariad Gene Therapeutics, Inc. Rapamycin-based biological regulation
WO1996040272A1 (en) * 1995-06-07 1996-12-19 University Of North Carolina At Chapel Hill Aav transduction of myoblasts
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
EP0906440A1 (en) * 1996-03-04 1999-04-07 Targeted Genetics Corporation Methods for transducing cells in blood vessels using recombinant aav vectors
IL128779A0 (en) * 1996-09-06 2000-01-31 Univ Pennsylvania Method for recombinant adeno-associated virus-directed gene therapy
US20020037867A1 (en) * 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
EP1017421B1 (en) 1997-03-07 2005-05-25 The Wistar Institute Of Anatomy And Biology Use of adenoviral vectors expressing VEGF or PDGF FOR HEALING TISSUE DEFECTS AND INDUCING HYPERVASCULARITY IN MAMMALIAN TISSUE
US6995006B2 (en) * 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6129757A (en) * 1998-05-18 2000-10-10 Scimed Life Systems Implantable members for receiving therapeutically useful compositions
AU763049B2 (en) * 1998-12-28 2003-07-10 Arch Development Corporation Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
WO2001048164A2 (en) 1999-12-27 2001-07-05 The Regents Of The University Of California Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
AU2001260214A1 (en) * 2000-04-13 2001-10-30 D. Collen Research Foudation Vzw Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease
ATE366319T1 (de) * 2000-08-17 2007-07-15 Keiya Ozawa Adeno-assoziierte virus-vermittelte übertragung von angiogenesefaktoren
EP1870473A1 (en) * 2000-08-17 2007-12-26 Keiya Ozawa Adeno-associated virus-mediated delivery of angiogenic factors
US20030064025A1 (en) * 2001-04-05 2003-04-03 Xiaoming Yang Imaging systems for in vivo protocols
AU2002303243A1 (en) * 2001-04-05 2002-10-21 The Johns Hopkins University Imaging nucleic acid delivery
AU2002331669A1 (en) 2001-08-23 2003-03-10 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
AU2003228410A1 (en) * 2002-04-01 2003-10-20 The Johns Hopkins University School Of Medicine Device, systems and methods for heating of a vessel in combination with mr/nmr imaging
US20040009151A1 (en) * 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
EP1486567A1 (en) * 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
US20060258980A1 (en) * 2003-09-19 2006-11-16 The Trustees Of The University Of Pennsylvania Global myocardial perfusion catheter
US20050244377A1 (en) * 2003-12-24 2005-11-03 Daniel Sigg Methods of treating cardiac disorders by suppressing the expression of the potassium inwardly-rectifying channel
US8859273B2 (en) * 2003-12-24 2014-10-14 Medtronic, Inc. Methods of using HCN genes to treat cardiac arrhythmias
US20060128647A1 (en) * 2003-12-24 2006-06-15 Daniel Sigg Novel oligonucleotides and treating cardiac disorders by using the same
US20050281786A1 (en) * 2004-06-18 2005-12-22 David Poulsen AAV mediated gene delivery to cochlear cells
CN1286981C (zh) * 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
AU2007277392A1 (en) * 2006-07-25 2008-01-31 Celladon Corporation Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy
AU2008350903B2 (en) 2008-02-19 2015-04-02 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US9644205B2 (en) 2012-04-25 2017-05-09 The Regents Of The University Of California Synthetic promoter for modulating gene expression
WO2016133917A1 (en) 2015-02-16 2016-08-25 University Of Florida Research Foundation Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5478745A (en) * 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
WO1995012681A1 (en) * 1993-11-05 1995-05-11 New York University Methods relating to ir-95
ATE272123T1 (de) * 1993-11-09 2004-08-15 Ohio Med College Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
US5693531A (en) * 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
US5580766A (en) * 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
DE9416814U1 (de) * 1994-10-19 1996-02-15 Poeting Gmbh & Co Kg Vorrichtung zur Herstellung von Glasformlingen nach dem Preßverfahren
EA001616B1 (ru) * 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents

Also Published As

Publication number Publication date
US6162796A (en) 2000-12-19
CA2233167A1 (en) 1997-04-03
AU7246796A (en) 1997-04-17
JPH11512608A (ja) 1999-11-02
EP0859853A1 (en) 1998-08-26
AU727835B2 (en) 2001-01-04
WO1997012050A1 (en) 1997-04-03

Similar Documents

Publication Publication Date Title
ZA968170B (en) Method for transferring genes to the heart using aav vectors
EP0688358A4 (en) IMPROVED VECTORS FOR GENTHERAPY
GB9524973D0 (en) Viral vectors
HUP0001650A3 (en) Improved expression vectors
IL117309A0 (en) Gene transfer-mediated angiogenesis therapy
AU2552795A (en) Safe vectors for gene therapy
GB9408982D0 (en) Propulsion system
IL114517A0 (en) Heart assist system
AU8672198A (en) Method enabling readministration of aav vector via immunosuppression of host
EP0845457A4 (en) 2,2-DIDEUTERO-5-AMINOLEVULINIC ACID
NZ286622A (en) Fluorophenylalkenylcarboxylic acid guanidides
GB2305614B (en) Modulator system for golf clubs
AU2404395A (en) Image-transfer process
GB9602388D0 (en) Improvements relating to merchandising apparatus
ZA9710114B (en) Method for the expression of genes.
ZA958381B (en) Regulated genes by stimulation of chondrocytes with 1l-1beta
GB9422495D0 (en) DNA transfer method
GB9503805D0 (en) Improvements relating to trolley transfer apparatus
EP0690360A3 (en) Polarizable transfer members made of polyurethane
AU4941096A (en) Self-deleting vectors for gene therapy
AU4369596A (en) Sperm as vaccine vectors
GB9518997D0 (en) Improvements relating to trolleys
PL317305A1 (en) Method of regenerating slip-rings
GB9517494D0 (en) Recominent DNA expression system
GB9519871D0 (en) Collapsible trolley